Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Recruiting 13Active not recruiting 6Unknown 4Terminated 3Completed 3Not yet recruiting 2Withdrawn 1Suspended 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Neuroendocrine Tumors 2Somatostatinoma 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Completed × lutetium Lu 177 dotatate × Clear all
NCT02230176 2025-04-20

OCCLURANDOM

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Completed
84 enrolled

Somatostatinoma

NCT04385992 2023-06-27

NeoLuPaNET

IRCCS San Raffaele

Phase 2 Completed
31 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT01237457 2023-03-20

177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms

Excel Diagnostics and Nuclear Oncology Center

Phase 2 Completed
143 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡